Li Jianwu, Jiang Na, Zeng Qing-Lei, Zhang Yue, He Xinyuan, Chu Yao, Jin Wenni, Liu Yi, Shi Wan, Yang Miao, He Weihan, Han Qing, Ma Le, Xu You, Guo Yaling, Zhang Lei, Ji Fanpu
Isolation Ward for Covid-19, the Eighth Hospital of Xi'an City, Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China.
Shaanxi Provincial Clinical Medical Research Center of Infectious Diseases, Xi'an, Shaanxi, People's Republic of China.
Infect Drug Resist. 2022 Apr 22;15:2115-2125. doi: 10.2147/IDR.S356460. eCollection 2022.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination had been demonstrated as an effective way to reduce the risk of coronavirus disease 2019 (COVID-19), and only a few vaccines suffered from SARS-CoV-2 infection. However, limited data concerning the clinical features of these vaccines infected with SARS-CoV-2 can be identified.
We retrospectively collected and analyzed epidemiological and clinical characteristics data of the imported COVID-19 cases who received Chinese inactivated vaccines abroad. Data were extracted from electronic medical records from a designated hospital in the Shaanxi Province of China between March 22 and May 17, 2021.
Totally, 46 confirmed SARS-CoV-2 infection patients were enrolled. The mean age was 40.5 years (range 20-61), 41 (89.1%) are male. Eighteen (39.1%) patients were from Pakistan. Fourteen (30.4%) patients had at least one comorbidity. Forty (87.0%) and 6 cases were fully vaccinated and partly vaccinated. The time interval between vaccination and infection was 88 days (IQR, 33-123), 31 (67.4%) and 15 (32.6%) were asymptomatic and symptomatic cases, respectively. Fever (3/46, 6.5%) was the most common symptom; however, none had a body temperature higher than 38.0°C, and no severe case was observed. Notably, the rate of SARS-CoV-2 shedding discontinuation at 7 days after hospitalization in asymptomatic cases was higher than symptomatic one (93.5% vs 40%, P < 0.0001).
Individuals who received Chinese inactivated vaccines abroad remain to have the probability of being infected with SARS-CoV-2, but all the vaccines infected with SARS-CoV-2 were asymptomatic or had mild symptoms with favorable clinical outcomes.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗接种已被证明是降低2019冠状病毒病（COVID-19）风险的有效方法，仅有少数接种疫苗者感染了SARS-CoV-2。然而，关于这些感染SARS-CoV-2的接种疫苗者临床特征的资料有限。
我们回顾性收集并分析了在国外接种中国灭活疫苗的输入性COVID-19病例的流行病学和临床特征数据。数据取自2021年3月22日至5月17日中国陕西省某指定医院的电子病历。
共纳入46例确诊的SARS-CoV-2感染患者。平均年龄为40.5岁（范围20 - 61岁），男性41例（89.1%）。18例（39.1%）患者来自巴基斯坦。14例（30.4%）患者至少有一种合并症。40例（87.0%）和6例患者分别为全程接种和部分接种。接种疫苗至感染的时间间隔为88天（四分位间距，33 - 123天），无症状和有症状病例分别为31例（67.4%）和15例（32.6%）。发热（3/46，6.5%）是最常见的症状；然而，体温均未高于38.0°C，未观察到重症病例。值得注意的是，无症状病例住院7天后SARS-CoV-2病毒载量停止排出的比例高于有症状病例（93.5%对40%，P < 0.0001）。
在国外接种中国灭活疫苗的个体仍有感染SARS-CoV-2的可能性，但所有感染SARS-CoV-2的接种疫苗者均为无症状或症状轻微，临床结局良好。
